Ksilink is working on diseases with a high medical need. By applying break-through technologies and know-how we are combining medical needs with market expectations and technical feasability.

Ksilink’s network of excellence: Derisking Innovation

The complexity of patient based models is transforming entrenched work patterns between public research and industry. Access to patient derived, disease-relevant models and the most adequate competences for analyzing phenotypic screening results is becoming a competitive game changer. From an industry perspective, it is critical who will first access the relevant models – and further to that, who is able to best implement these models into the drug discovery process. Beside our in house expertise, Ksilink has access to a constantly growing network of leading clinicians and academics in France and Germany. Once the right partners are identified, Ksilink drives its collaborative drug discovery projects in a highly industrialized and standardized surrounding.  Ksilink thus offers a critical advantage to its clients– with its established expertise it can generate validated patient based models within a short time.

Integrated Approach


Psychiatric disorders are brain disorders of complex and variable genetic risk affecting over 15% of the population. The last decade has witnessed exciting and important advances in neuroscience of mental health including the mapping of neural circuitry and neurochemical mechanisms, identification of multiple genetic loci etc. Ksilink develops and validates valuable cellular iPSC based disease models from patients with psychiatric diseases such as schizophrenia for further target free drug discovery and development approaches.


Muscular Dystrophies are among the most common human genetic diseases. In general there is no cure for dystrophies and current treatments are limited to palliative care. The development of therapeutic treatments on the basis of a well characterized human iPSC based isogenic disease model is a real challenge and worldwide unique.


Cardiomyopathies are a significant cause of heart failure and a leading indication for heart transplant among children and adults across the globe. Genetic inheritance with single gene mutations is found to affect a large group of patients with cardiomyopathies such as dilated cardiomyopathy or Catecholaminergic Polymorphic Ventricular Tachycardia. We develop new therapeutics against cardiomyopathies.


The communication between cancer and the immune system is a dynamic process, reminiscent of a balance. When immunity to cancer is ‘‘up’’ and the suppressive processes are ‘‘down,’’ cancer is under control. Sometimes this balance shifts and cancer appears. Ksilink is establishing complex but valuable cellular models to fight cancer by developing new therapeutics.


The term ‘neurodegeneration’ involves a few diseases such as Alzheimer, Parkinson and Huntington’s disease affecting a constantly increasing population. The current market has no curative therapies and thus, available medications can only provide symptomatic relief. The market, hence, has a high potential for growth and should be tapped at the earliest. Ksilink can drive novel iPSC based disease model for subsequent drug discovery and development projects.